Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

NCT00102024 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Metastases

Interventions

DRUG: Unconjugated IDEC-159
DRUG: 111In-IDEC-159
DRUG: 90Y-IDEC-159

Sponsor

Biogen